Compare EXPD & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EXPD | PODD |
|---|---|---|
| Founded | 1979 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.6B | 17.0B |
| IPO Year | 1995 | 2007 |
| Metric | EXPD | PODD |
|---|---|---|
| Price | $138.83 | $245.25 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 10 | 22 |
| Target Price | $131.70 | ★ $352.86 |
| AVG Volume (30 Days) | ★ 1.7M | 1.1M |
| Earning Date | 01-01-0001 | 05-20-2026 |
| Dividend Yield | ★ 1.03% | N/A |
| EPS Growth | ★ 14.17 | N/A |
| EPS | ★ 4.46 | 3.48 |
| Revenue | ★ $6,920,948,000.00 | $2,708,100,000.00 |
| Revenue This Year | $6.12 | $22.19 |
| Revenue Next Year | N/A | $18.68 |
| P/E Ratio | ★ $33.59 | $71.63 |
| Revenue Growth | 13.49 | ★ 30.73 |
| 52 Week Low | $100.47 | $230.08 |
| 52 Week High | $167.19 | $354.88 |
| Indicator | EXPD | PODD |
|---|---|---|
| Relative Strength Index (RSI) | 35.58 | 41.28 |
| Support Level | $111.45 | $240.33 |
| Resistance Level | $165.83 | $299.75 |
| Average True Range (ATR) | 6.27 | 9.56 |
| MACD | -1.68 | 1.37 |
| Stochastic Oscillator | 30.93 | 23.92 |
Based in the US, Expeditors International of Washington is a non-asset-based third-party logistics provider, mainly focused on international freight forwarding. Its offers freight consolidation and forwarding, customs brokerage, warehousing and distribution, purchase order management, vendor consolidation, and numerous other value-added logistics services. It employs sophisticated IT systems and contracts with airlines and ocean carriers to move customers' freight across the globe. The firm operates more than 200 full-service office locations worldwide, in addition to numerous satellite locations. Expeditors derives around 35% of consolidated gross revenue from airfreight, 30% from ocean freight, and 36% from customs brokerage and other services.
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.